Folia Pharmacologica Japonica
Online ISSN : 1347-8397
Print ISSN : 0015-5691
ISSN-L : 0015-5691
Review on New Drug
Neoral® (Cyclosporin microemulsion preconcentrate): Pharmacokinetics, pharmacodynamics and its improved clinical outcome
Yoko NISHI
Author information
JOURNAL FREE ACCESS

2001 Volume 118 Issue 2 Pages 107-115

Details
Abstract
Sandimmun displays considerable inter- and intra-patient variability because its absorption is biledependent and affected by concomitant intake of food. Neoral is a microemulsion preconcentrate; a microemulsion is a mixture of the lipophilic active substance with accurately balanced amounts of lipophilic solvent, hydrophilic solvent and surfactant. As the result of advanced microemulsion technique, Neoral has more consistent and improved absorption characteristics. Cyclosporin (cyclosporin A) has been used as an immunosuppressive agent. The major pharmacodynamic action of cyclosporin within T cells is calcineurin inhibition. The complex cyclophilin-cyclosporin competitively binds to the Ca2+- and calmodulin-dependent phosphatase calcineurin wihch then inhibits downstream dephosphorylation and activation of NFAT(transcription factor). The greatest calcineurin inhibition is seen 1-2 h after administration of Neoral in parallel to the highest blood concentration. Variability in cyclosporin exposure was also identified as a risk factor for acute rejection in organ transplant recipients. “Absorption profiling” provides a more accurate prediction of drug exposure and leads to less acute rejection and toxicity. The evolution of Neoral monitoring strategies from trough level to absorption profile will raise the standard of performance of Neoral, resulting in clinical benefits for transplant patients.
Content from these authors
© 2001 by The Japanese Pharmacological Society
Previous article Next article
feedback
Top